Amgen Drug Patent Portfolio
Amgen owns 1 orange book drug protected by 6 US patents Given below is the list of Amgen's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7829595 | Rapid dissolution formulation of a calcium receptor-active compound | 22 Sep, 2026 | Active |
| US9375405 | Rapid dissolution formulation of a calcium receptor-active compound | 22 Sep, 2026 | Active |
| US6011068 | Calcium receptor-active molecules | 08 Mar, 2018 | Expired |
| US6031003 | Calcium receptor-active molecules | 14 Dec, 2016 | Expired |
| US6313146 | Calcium receptor-active molecules | 14 Dec, 2016 | Expired |
| US6211244 | Calcium receptor-active compounds | 23 Oct, 2015 | Expired |
Latest Legal Activities on Amgen's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Amgen.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 21 Nov, 2023 | US9375405 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 21 Apr, 2022 | US7829595 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 13 Dec, 2019 | US9375405 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 27 Apr, 2018 | US7829595 |
| Post Issue Communication - Certificate of Correction | 13 Feb, 2018 | US9375405 |
|
Recordation of Patent Grant Mailed
Critical
| 28 Jun, 2016 | US9375405 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 28 Jun, 2016 | US9375405 |
|
Issue Notification Mailed
Critical
| 08 Jun, 2016 | US9375405 |
|
Application Is Considered Ready for Issue
Critical
| 25 May, 2016 | US9375405 |
| Dispatch to FDC | 25 May, 2016 | US9375405 |
|
Issue Fee Payment Received
Critical
| 24 May, 2016 | US9375405 |
|
Issue Fee Payment Verified
Critical
| 24 May, 2016 | US9375405 |
| Printer Rush- No mailing | 20 May, 2016 | US9375405 |
|
Information Disclosure Statement considered
Critical
| 19 May, 2016 | US9375405 |
|
Pubs Case Remand to TC
Critical
| 16 May, 2016 | US9375405 |
Amgen's Drug Patent Litigations
Amgen's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Oct 26, 2015, against patent number US7829595. The petitioner , challenged the validity of this patent, with None as the respondent. Click below to track the latest information on how companies are challenging Amgen's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US7829595 | October, 2015 |
Terminated-Denied
(13 Apr, 2016)
| ||
Amgen Drug Patents' Oppositions Filed in EPO
Amgen drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Oct 14, 2013, by Actavis Group Ptc Ehf. This opposition was filed on patent number EP04781429A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP17185704A | May, 2021 | PUREN Pharma GmbH & Co. KG | Granted and Under Opposition |
| EP17185704A | Apr, 2021 | Aristo Pharma GmbH | Granted and Under Opposition |
| EP17185704A | Mar, 2021 | TAD Pharma GmbH | Granted and Under Opposition |
| EP18175497A | Dec, 2020 | Hexal AG | Revoked |
| EP18175495A | Dec, 2020 | betapharm Arzneimittel GmbH | Revoked |
| EP18175497A | Dec, 2020 | betapharm Arzneimittel GmbH | Revoked |
| EP17185704A | Nov, 2020 | betapharm Arzneimittel GmbH | Granted and Under Opposition |
| EP18175495A | Jan, 2020 | Accord Healthcare Ltd | Revoked |
| EP18175495A | Jan, 2020 | HGF Limited | Revoked |
| EP18175495A | Jan, 2020 | BIOGARAN | Revoked |
| EP18175495A | Jan, 2020 | Aechter, Bernd | Revoked |
| EP18175495A | Jan, 2020 | Glenmark Pharmaceuticals Europe Ltd | Revoked |
| EP18175499A | Jan, 2020 | HGF Limited | Revoked |
| EP18175499A | Jan, 2020 | Aechter, Bernd | Revoked |
| EP18175499A | Jan, 2020 | Accord Healthcare Ltd | Revoked |
| EP18175497A | Jan, 2020 | BIOGARAN | Revoked |
| EP18175497A | Jan, 2020 | Zentiva, k.s. | Revoked |
| EP18175497A | Jan, 2020 | MAIWALD PATENTANWALTS- UND RECHTSANWALTSGESELLSCHAFT MBH | Revoked |
| EP18175497A | Jan, 2020 | Aechter, Bernd | Revoked |
| EP18175497A | Jan, 2020 | Accord Healthcare | Revoked |
| EP17185704A | Jan, 2020 | Accord Healthcare Ltd | Granted and Under Opposition |
| EP17185704A | Jan, 2020 | BIOGARAN | Granted and Under Opposition |
| EP17185704A | Jan, 2020 | HGF Limited | Granted and Under Opposition |
| EP17185704A | Jan, 2020 | Aechter, Bernd | Granted and Under Opposition |
| EP18175499A | Jan, 2020 | BIOGARAN | Revoked |
| EP18175499A | Jan, 2020 | MAIWALD PATENTANWALTS- UND RECHTSANWALTSGESELLSCHAFT MBH | Revoked |
| EP18175497A | Jan, 2020 | Glenmark Pharmaceuticals Europe Ltd | Revoked |
| EP18175497A | Jan, 2020 | Gillard, Richard Edward | Revoked |
| EP18175497A | Jan, 2020 | HGF Limited | Revoked |
| EP18175499A | Jan, 2020 | Hamm&Wittkopp Patentanwälte PartmbB | Revoked |
| EP18175499A | Jan, 2020 | Gillard, Richard Edward | Revoked |
| EP18175499A | Jan, 2020 | Glenmark Pharmaceuticals Europe Ltd | Revoked |
| EP17185704A | Jan, 2020 | Glenmark Pharmaceuticals Europe Ltd | Granted and Under Opposition |
| EP17185704A | Jan, 2020 | Teva Pharmaceutical Industries Ltd. | Granted and Under Opposition |
| EP18175495A | Jan, 2020 | Teva Pharmaceutical Industries Ltd | Revoked |
| EP18175497A | Jan, 2020 | Teva Pharmaceutical Industries Ltd | Revoked |
| EP18175499A | Jan, 2020 | Teva Pharmaceutical Industries Ltd | Revoked |
| EP04781429A | Oct, 2013 | ZBM PATENTS, S.L. | Patent maintained as amended |
| EP04781429A | Oct, 2013 | RAFARM S.A. | Patent maintained as amended |
| EP04781429A | Oct, 2013 | Actavis Group PTC EHF | Patent maintained as amended |
Amgen's Family Patents
Amgen Drug List
Given below is the complete list of Amgen's drugs and the patents protecting them.
1. Sensipar
Sensipar is protected by 6 patents, out of which 4 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7829595 | Rapid dissolution formulation of a calcium receptor-active compound |
22 Sep, 2026
(1 year, 8 months from now)
| Active |
| US9375405 | Rapid dissolution formulation of a calcium receptor-active compound |
22 Sep, 2026
(1 year, 8 months from now)
| Active |
| US6011068 | Calcium receptor-active molecules |
08 Mar, 2018
(6 years ago)
| Expired |
| US6031003 | Calcium receptor-active molecules |
14 Dec, 2016
(8 years ago)
| Expired |
| US6313146 | Calcium receptor-active molecules |
14 Dec, 2016
(8 years ago)
| Expired |
| US6211244 | Calcium receptor-active compounds |
23 Oct, 2015
(9 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Sensipar's drug page